3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
Oxaliplatin
26
Gemcitabine
22
Fluorouracil
17
Capecitabine
16
Leucovorin
15
pembrolizumab
14
Docetaxel
14
Cisplatin
13
Bevacizumab
12
Radiotherapy
8
Paclitaxel
8
Irinotecan
8
Trastuzumab
7
Pemetrexed
6
Carboplatin
6
130-nm albumin-bound paclitaxel
6
durvalumab
5
cemiplimab
5
Erlotinib Hydrochloride
5
Sunitinib
4
Ramucirumab
4
Metformin
4
Gefitinib
4
trastuzumab deruxtecan
3
tislelizumab
3
cabozantinib
3
atezolizumab
3
Taxes
3
Sorafenib
3
Panitumumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adenocarcinoma
×
matuzumab
×
Clear all
NCT00215644
2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
72 enrolled
7 charts